“One year after the launch of Diabeta, I can’t help but reflect on the incredible journey and impact it has had on diabetes care. As Co-Founder of Apollo AI Technologies, I want to express my sincere thanks to our doctors and partners for their essential contribution to this extraordinary achievement. Diabeta is not just a medical platform, it is a paradigm shift in diabetes management, and this success would not have been possible without their support and dedication,” said Mihaela Onofrei, CEO Apollo AI Technologies at the time of celebrating the first year since the launch of DIABETA.
Diabeta is the first medical chatbot approved by the National Agency for Medicines and Medical Devices (NAMMD). This innovative platform brings to the fore an innovative approach to diabetes management, ensuring access to accurate and verified information in real time. Diabeta processes an extensive database of information from official diabetes guidelines and protocols, as well as Feature Summaries of Products used in the National Diabetes Program, to provide quick and accurate answers to questions related to available diabetes treatments.
THANKS TO CONTRIBUTORS
On the anniversary moment, Mihaela Onofrei thinks of those who have contributed significantly to the development of Diabeta.
“To the doctors who quickly adopted Diabeta, thank you for your trust in technology and for actively using our platform to provide the best care for patients with diabetes.
To our trusted partners, Novo Nordisk, Boehringer-Ingelheim and Medtronic, thank you for your constant partnership and unconditional support. Our collaboration has been key to bringing Diabetes alive and making it possible to revolutionize diabetes management.
With her expertise, passion and clear vision, Assoc. Prof. Anca Pantea Stoian, PhD, scientific coordinator of this project, was the person who guided the team in creating and evolving this innovative platform. Thank you for your exemplary dedication and for being an inspirational source for our entire community,” said Mihaela Onofrei.
CONTINUOUS INNOVATION
The future plans for Diabeta are just as spectacular. “This year, Diabeta has become a reference point in medical innovation, and this is due to the joint efforts of doctors and our partners. We are proud to have been able to provide a solution that makes a difference in patients’ lives and are excited about the future in which Diabeta will continue to make significant improvements in healthcare. Thank you to everyone involved in this project and for joining us on this extraordinary journey. I look forward to continuing to work together to bring medical innovation to the next level and make a real difference in patient health,” continued the CEO of Apollo AI Technologies.
The innovative Diabeta platform was created by the Romanian company Apollo AI Technologies, thus representing an example of innovation in the medical industry in Romania. Diabeta also benefits from the strong support of healthcare industry partners such as Novo Nordisk, Boehringer Ingelheim and Medtronic, companies with strong reputations in the medical field.
